The abstract acknowledges that well-designed clinical trials are still needed to establish metformin as a geroprotector. This represents a critical knowledge gap for translating promising observational data into evidence-based neuroprotective interventions for age-related cognitive decline. Gap type: open_question Source paper: The Use of Metformin to Increase the Human Healthspan. (2020, Advances in experimental medicine and biology, PMID:32304040)
Landscape Summary: What are the optimal dosing regimens and treatment duration for metformin's neuroprotective effects in aging populations? is a 0.83 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What are the optimal dosing regimens and treatment duration for metformin's neuroprotective effects in aging populations? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: